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                                     Introduction 
        Stroke was defined according to the World Health Organization criteria 
as “rapidly developing symptoms and/or signs of focal, and at times global, 
loss  of  cerebral  function,  with  symptoms  lasting  more  than  24  hours  or 
leading to death with no apparent cause other than that of vascular origin.” 
The term “global” refers mainly to subarachnoid hemorrhage. 
      Recurrent stroke1, 31 is defined as a stroke, in which (1) there was clinical 
evidence of  the  sudden onset  of  a  new focal  neurological  deficit  with  no 
apparent cause other than that of vascular origin (ie, the deficit could not be 
ascribed  to  an  intercurrent  acute  illness,  epileptic  seizure,  or  toxiceffect) 
occurring at any time after the index stroke; or (2) there was clinical evidence 
of the sudden onset of an exacerbation of a previous focal neurological deficit 
with no apparent cause other than that of vascular origin occurring 21 days 
after the index stroke. 
Each  recurrent  stroke  was  classified  as  ischemic,  hemorrhagic,  or  of 
undetermined nature on the basis of a CT or MRI scan performed within 28 
days of recurrence or autopsy examination of the brain. Etiologic subtypes of 
ischemic stroke were defined according to Standardized criteria. 
      Conceptically the following definition is applicable in a community based 
study .Recurrence represents the proportion of patients with stroke who had a 
second  stroke  during  a  specified  period  of  observation.  For  example 
cumulative recurrence of stroke  after surviving the first cerebral infarction in 
a  population  based  study  of  Rochester  ,Minnesota  residents  was 
approximately  6%.19%,29% at 1,5&10 years respectively.
         If a stroke occurred during time interval 3-21 days, it often had to be in 
a  different  vascular territory  or  anatomical  site  from the  first  event,  of  a 
different stroke subtype, or result in a different neurological deficit, in order 
to be considered a recurrence. 
A  neurological  worsening  occurring  at  any  time  after  the  index  event, 
following  a  period  of  stability  of  24  h  should  be  considered  a  potential 
recurrent  stroke.  This  will  not  allow the  very  early  recurrence  risk  to  be 
underestimated.
      Stroke-in-progression has been defined by the European Stroke Database 
collaboration as ‘neurological progression occurring within the first 3 days’. 
              There is a considerable variance of crude prevalence rates of 
cerebrovascular diseases across India. Vellore & Rohtak gave rates of 13& 
33 per  100000 respectively(low) to  270 in  Guwahathi,  Assam. The crude 
prevalence rate varied from 45-843 per 100000   with a high frequency of 
diabetes & poorly controlled. Hypertension patients with stroke are seen very 
frequently in daily Indian practice. Age adjusted mortality rates from stroke 
are considerably higher among Indians as against Europeans.
                       The immediate period after stroke comes the greatest risk for 
recurrence in stroke databank of 1273 patients with infarcty 3.3% had early 
recurrence within 30 days. Long term stroke recurrence range from 4% to 
14% with aggregate annual estimate of 6.1% for minor and 9% for major 
stroke.
                       Based on WHO task force report on stroke prevention 
diagnosis and therapy-1989, it appeared that for large artery hypertension & 
smoking elevated blood lipid levels, obesity & diabetes are more important 
modifiable risk factors. Cardio embolic stroke, RHD&IHD seem to be the 
dominant  risk factors  among Indians.  Broderick & Swanson of  Rochester 
study reported a 1% annual stroke recurrence in patients with a mean follow 
up of  7  years(Broderick  &Swanson 1987).This  rate  is  significantly  lower 
than the 9% reported by Rothrock In This study the incidence of recurrent 
stroke,  various  subtypes  of  presentation,  etiologies,  risk  factors  and  the 
effects of attempts at correction are analyzed.                          
The  precise  arterial  pathology  underlying  lacunar  infarcts, which  are 
presumed to result from the occlusion of single, small perforating arteries, 
remains  undetermined.  It  is  often  assumed  to  differ  from  the 
atherothromboembolic processes  that  occlude  large  intracranial  and 
extracranial  arteries and  cause  most  other  types  of  ischaemic  stroke. 
However, evidence from direct pathological studies is limited because lacunar 
infarction has a low case fatality, autopsy rates are declining, and informative 
pathological  studies  are  expensive,  technically demanding  and  time-
consuming. 
Informative  imaging  studies  are  also  scarce  because  of  the  difficulties in 
imaging small arteries. Alternative, less direct methods have therefore been 
used  to  study  the  pathology  of  lacunar  infarction. These  have  included 
observational  studies  comparing  the  risk factor  profiles  and  prognosis  of 
patients with lacunar versus non-lacunar infarction, since differences might 
suggest distinct arterial pathologies.  Systematic review of studies comparing 
risk factor profiles in lacunar versus non-lacunar infarction found an excess 
of atrial fibrillation and severe carotid stenosis among non-lacunar infarction 
patients, but no clear difference in the frequency of any other risk factors, 
including hypertension and diabetes. 
Aim of the study
 To study 
*The clinical profile,
*Patterns of vascular involvement.
*Possible etiologies,
*Risk factors identified during the first episode of stroke.
*Risk factors persistent /corrected  in the second or subsequent                  
   stroke episodes. 
*Effects of risk factor treatment on stroke free interval and the
  occurrence of  recurrent stroke
Review of literature
 Incidences of recurrent stroke are reported by prospective and retrospective 
studies  as  hospital  based  and  community  based.  Stroke  during  its  first 
occurrence and recurrence are analyzed on the basis  of vascular  territory, 
clinico pathological  types used as in Oxfordshire community based study, 
Toast classification for the risk factors. 
      Graeme J. Hankey,etal’s1 community-based study aimed to determine the 
absolute and relative risks of a first recurrent stroke over the first 5 years after 
a first-ever stroke and the predictors of such recurrence in a population-based 
series of people with first-ever stroke in Perth, Western Australia from 1989. 
All people with a suspected acute stroke or transient ischemic attack of the 
brain who were resident in a geographically defined region of Perth, with a 
population of 138 708 people,  were registered prospectively and assessed. 
Patients were followed up prospectively at 4 months, 12 months, and 5 years 
after the index event. Three hundred seventy patients with a first-ever stroke 
were registered, of whom 351 survived. Data were available for 98% of the 
cohort at 5 years, by which time 199 patients (58%) had died and 52 (15%) 
had experienced a recurrent stroke, 12 (23%) of which were fatal within 28 
days. The 5-year cumulative risk of first recurrent stroke was 22.5% (95% 
confidence  limits  [CL],  16.8%,  28.1%).  The  risk  of  recurrent  stroke  was 
8.8%- greatest in the first 6 months after stroke. (95% CL, 5.4%, 12.1%). 
After adjustment for age and sex, the prognostic factors for recurrent stroke 
were advanced, but not extreme, age (75 to 84 years) (hazard ratio [HR], 2.6; 
95% CL, 1.1, 6.2), hemorrhagic index stroke (HR, 2.1; 95% CL, 0.98, 4.4), 
and diabetes mellitus (HR, 2.1;  95% CL, 0.95, 4.4).Approximately 1 in 6 
survivors (15%) of a first-ever stroke experience a recurrent stroke over the 
next  5  years,  of  which  25%  are  fatal  within  28  days.  The  pathological 
subtype of the recurrent stroke is the same as that of the index stroke in 88% 
of cases. The predictors of first recurrent stroke in this study were advanced 
age,  hemorrhagic  index  stroke,  and  diabetes  mellitus,  but  numbers  of 
recurrent events were modest. Because the risk of recurrent stroke is highest 
(8.8%) in the first 6 months after stroke, strategies for secondary prevention 
should be initiated as soon as possible after the index event.  
Jung  B  et  al  5  did  a  community-based  epidemiologic  study.  All  patients 
enrolled  as  acute  ischemic  stroke  patients  from  Jan.  1998  to  Dec.  2000 
analyzed to  identify  the  factors  responsible  for  recurrent  ischemic  stroke. 
Among  599  patients  with  ischemic  stroke,  43  patients  (7.2%)  were  had 
recurrent  stroke  (27  men  and  16  women;  mean  age=66.3  years). 
Hypertension  and  hyperlipidemia  were  the  risk  factors  which  were 
statistically significant in inducing recurrent ischemic stroke. According to 
the TOAST classification, cardio embolism was more prevalent in recurrent 
ischemic stroke. 
         Jean-Louis Mas 2 et al studied the risks of recurrent cerebrovascular 
events associated with patent foramen ovale and atrial septal aneurysm .  A 
total of 581 patients (age, 18 to 55 years) who had had an ischemic stroke of 
unknown  origin  within  the  preceding three  months  were  consecutively 
enrolled at 30 neurology centers. All patients received aspirin (300 mg per 
day) for secondary prevention. After four years, the risk of  recurrent stroke 
was 2.3 percent (95 percent confidence interval, 0.3 to 4.3 percent) among the 
patients with patent foramen ovale alone, 15.2 percent (95 percent confidence 
interval, 1.8 to 28.6 percent) among the patients with both patent foramen 
ovale  and  atrial  septal aneurysm,  and  4.2  percent  (95  percent  confidence 
interval, 1.8 to 6.6 percent) among the patients with neither of these cardiac 
abnormalities. There were no recurrences among the patients with an atrial 
septal  aneurysm alone.  The  presence  of  both  cardiac abnormalities  was  a 
significant predictor of an increased risk of recurrent stroke (hazard ratio for 
the  comparison  with  the absence  of  these  abnormalities,  4.17;  95  percent 
confidence interval, 1.47 to 11.84), whereas isolated patent foramen ovale, 
whether small or large, was not
              Andy H.et al  3 reported Of the 678 patients in the cohort, 124 
(18.3%) experienced repeated episodes of ischaemic stroke. Rural residence 
and carotid  endarterectomy procedure  were  positively  associated  with  the 
recurrence frequency, the adjusted incidence rate ratio being 1.66 (95% CI: 
1.17–2.36)  and  3.96  (95%  CI:  2.30–6.82),  respectively.  Rural  patients 
contributed to 18% of the patients in the cohort yet they accounted for 27% 
of  those  sustaining  repeated  episodes  of  stroke.  Readmissions  were  also 
related to the presence of diabetes at the index episode. 
           Goldstein  et al 4 identified all patients admitted to Duke University 
Hospital or the Durham Veterans Administration Medical Center during 1 
year having two documented ischemic strokes within 90 days (n=12 of 273). 
Twelve randomly selected patients matched for age, sex, and race but having 
only a single stroke served as controls. There were no significant differences 
between the groups with respect to a variety of factors including the presence 
of hypertension, diabetes, a history of transient ischemic attack, a history of 
stroke, cerebral site of the index stroke, and subtype of the index stroke. A 
potential cardioembolic source was more frequently identified in the patients 
with  early  recurrent  stroke  (seven  of  the  12  case-control  pairs  were 
discordant for a potential cardioembolic source.
      Dong-wha kang et  al 7    in  a  retrospective  study  reports  that  Prior 
observations have shown that  early  recurrent ischemic lesions (ERILs)  on 
diffusion-weighted imaging occur frequently within the first  week after an 
index stroke. They included 133 patients who experienced an acute ischemic 
stroke and who underwent initial diffusion-weighted imaging within 24 hours 
and subsequent  diffusion-weighted imaging within 7 days after  onset,  and 
whose stroke subtype was Intra cranial large artery atherosclerosis(IC-LAA), 
extra  cranial  LAA (EC-LAA),  or cardio embolism (CE).   Early  recurrent 
ischemic  lesions were  defined  as  new  ischemic  lesions  on  follow-up 
diffusion-weighted imaging,  separate  from the  index  stroke  lesion.  Early 
recurrent ischemic lesions were observed in the following proportions: 50.9% 
(28/55) in the IC-LAA group, 47.4% (9/19) in the EC-LAA group, and 44.1% 
(26/59)  in  the  CE group.  Early  recurrent  ischemic lesions in  the  IC-LAA 
group had the following characteristics: (1) they occurred mostly (27 [96.4%] 
of 28) in the pial area of the same vascular territory as the index stroke; (2) 
they were more frequently  observed in  a  higher  grade of  stenosis  than in 
milder  stenosis  (P<.001), whereas  ERILs in  the  EC-LAA group were  not 
related to the degree of stenosis; (3) they were not associated with subsequent 
recanalization, whereas ERILs in the CE group were mostly associated with 
subsequent recanalization  (P<.001);  and  (4)  they  were  more  closely 
associated with clinical recurrence than in the EC-LAA or CE group (P=.02). 
They conclude that Early recurrent ischemic lesions in the IC-LAA group are 
relatively frequent and have different patterns than in the EC-LAA or CE 
group.
           Secondary prevention of recurrent stroke by treating the modifiable 
risk  factors  have  been  done  in  many  landmark  trials. The  prevention  of 
stroke, with its attendant costs,  both financial and personal,  is the goal of 
most  physicians, but  there is good evidence that modification of risk factors 
will  reduce  stroke  risk.   We’ll  look  at  the  evidence  for  the  following 
interventions:  treatment  of  hyperlipidemia,  smoking  cessation,  antiplatelet 
therapy, treatment of hypertension and anticoagulation for atrial fibrillation. 
 Aggressive  treatment  of  dyslipidemia  decrease  the  risk  of  stroke.
         This issue has been looked at indirectly in multiple placebo-controlled 
trials,  as  a  pre-specified  secondary  end  point.  Perhaps  the  best  place  to 
demonstrate this is to look at the MRC/BHF study, commonly known as the 
Heart Protection Study. This is the largest trial ever done on lipid lowering. It 
included 20,536 people aged 40 to 80 with coronary disease, other occlusive 
arterial disease or diabetes with a non fasting cholesterol >3.5 mm/l. There 
were 6,793 subjects with a starting LDL < 3mm/l. They were randomized to 
40 mg of simvastatin or a matching placebo. Follow up was for an average of 
5 years. 4.3% of the simvastatin group vs. 5.7% of the placebo group suffered 
a  stroke.  (RR  75%,  RRR  25%,  ARR  1.4%  NNT  71).  This  small  but 
consistent effect is seen in multiple trials. There were no excess hemorrhagic 
strokes in the treatment arm. 
               Smoking increases the risk of stroke.Clearly we do not have the best 
Level 1 evidence here as no randomized controlled trials have been done on 
this subject. In issues of harm, RCTs are impossible to do, as it is ethically 
impossible to randomize people to a smoking arm! So we have to look at the 
next best evidence, a prospective cohort trial, which systematically follows a 
large group of healthy people until they get ill with the disease of interest, 
and then tries to elucidate the risk factors for that outcome. 
           The Framingham Study 19 began soon after WWII, is still ongoing, and 
is the longest running prospective study of this type. In 1988, it reported on 
cigarette  smoking as  a  risk factor  for  stroke.  It  looked at  4,255 men and 
women, 36 to 68 years old and free of cerebrovascular disease. During a 26-
year  follow  up  459  strokes  occurred.  Multivariate  analysis  using  Cox 
proportional  hazard  modeling,  demonstrated  cigarette  smoking  as  an 
independent risk factor for all strokes in general, and thrombotic strokes in 
particular. The risk of stroke increased as the number of cigarettes smoked 
increased.  The  RR  was  double  in  heavy  smokers  (>  40  cigarettes/  day) 
compared to light smokers (< 10 cigarettes/day). Lapsed smokers retained 
their increased risk for the first 2 years, which then gradually decreased over 
the next 3 years. By 5 years the risk dropped to the level of non-smokers. 
Regardless of smoking status or sex, hypertension doubled the risk of stroke. 
           In 1989 a case controlled study20 looked at 621 patients with stroke 
and 573 controls without stroke. The authors estimated an increased relative 
risk of 1.5 for every 10 cigarettes consumed daily, both in men and women. 
The use of antiplatelet medications in the secondary prevention of stroke has 
long been established. Various drugs and combinations of drugs have been 
studied  over  the  last  20  years.  We  will  look  at  the  evidence  for  ASA, 
clopidogrel, and ASA plus dipyridamole. 
Acetyl  salicylic  acid  is  the  best  studied,  cheapest,  and  most  widely  used 
antiplatelet  medication.  In  1994  the  Antiplatelet  Trialists'  Collaboration 
published  a  meta-analysis  of  randomized  trials21 of  prolonged  antiplatelet 
therapy for prevention of stroke (along with various other endpoints). This 
meta-analysis looked at  trials published till  1990, the vast majority of the 
patients having taken ASA. Amongst 10,000 patients with a past history of 
stroke or TIA the net event rate for vascular events was estimated at 18% 
with antiplatelet therapy vs 22% in the controls. (RR 82%, RRR 18%, ARR 
4%, NNT 25). 
Ticlopidine was the first antiplatelet drug demonstrated to be clearly better 
than ASA, however it is not commonly used due to a poor side effect profile. 
The second drug in this class to be released was clopidogrel, along with the 
results of the CAPRIE trial. 
The CAPRIE Trial22 was a randomized,  double blinded,  international  trial 
designed to assess the relative efficacy of clopidogrel (75 mg. once daily) and 
aspirin (325 mg. once daily), in reducing the risk of a composite outcome 
cluster  of  ischemic  stroke,  myocardial  infarction,  or  vascular  death.  The 
population  studied  comprised  subgroups  of  patients  with  atherosclerotic 
vascular  disease  manifested  as,  either  recent  ischemic  stroke,  recent 
myocardial  infarction,  or  symptomatic  peripheral  arterial  disease.  19,185 
patients were followed for 1 to 3 years. The primary study end point was a 
composite  of  ischemic  stroke,  MI  or  vascular  death.  Overall,  in  all  3 
subgroups, there was an annual 5.32% event rate in the clopidogrel group vs 
5.83% in the ASA group. (RR 91.3%, RRR 8.7%, ARR 0.51%, NNT 196/per 
year, p=0.043). 
This is not an impressive result and required a huge study to demonstrate it. 
In  the sub group of  interest  to us,  the  6411 patients with a stroke as the 
qualifying  event  to  enter  the  trial,  clopidogrel  did  not  demonstrate  a 
significant  reduction in the  composite  endpoint.  (RRR 7.3% p=0.26).  (An 
argument can be made that this was just type 2 error and we just need a larger 
study to demonstrate a significant difference - but this was already a huge 
study). Also remember this data is for a composite end point whilst we are 
most interested here in secondary stroke prevention. So we can conclude that 
clopidogrel  has  not  been  demonstrated  to  be  superior  to  ASA  in  the 
secondary  prevention  of  stroke.  Further  analysis  of  this  trial  supports  the 
view that clopidogrel is clearly superior to ASA in the prevention of MI in 
the CAPRIE patient population. (RRR 16.6% NNT 119) 
By the late 1980's dipyridamole and the combination with ASA was felt to be 
no better than ASA alone. However, in 1987 ESPS-1 using a combination of 
ASA  330  mg.  plus  dipyridamole  TID  for  2  years  in  patients  with  prior 
ischemic stroke or TIA, showed a RRR of 38% for subsequent stroke. This 
was far  higher than expected from previous studies on ASA alone.  There 
were a lot of questions about the dosing of ASA and the conflicting data of 
ESPS-1 vs previous trials, so a larger 2x2 factorial design study, ESPS-28 
was undertaken in 1989 and published in 1996. Placebo was compared to 
ASA  25  mg.  BID,  dipyridamole  200  mg.  extended  release,  and  the 
combination  of  ASA  plus  dipyridamole.  Patients  with  a  prior  TIA  or 
ischemic CVA were enrolled and followed for 2 years in this international 
multicenter randomized double blinded trial done in Europe. 
The results were impressive. 15.78% of the placebo group, 13.21% of the 
dipyridamole  group,  12.93%  of  the  ASA  group  and  9.95%  of  the 
combination  group  suffered  a  recurrent  stroke.  There  was  no  statistical 
difference between the 2 active treatment groups and with a RRR of 18%, the 
low dose ASA group was in line with previous trials on ASA. The surprise 
was the additive effect seen in the combination group. (RR 63%, RRR 37%, 
ARR 5.83%, p<0.001, NNT 17 over 2 years). There was no difference in the 
death rate in the 4 groups and no excess of MI in the combination group. 
From the evidence it is clear the first choice in secondary prevention should 
be a combination of low dose ASA plus extended release dipyridamole. It is 
superior  to  ASA  or  clopidogrel  alone.  The  combination  of  ASA  and 
clopidogrel. There is good evidence to use it for ischemic heart disease but 
the evidence is lacking for secondary prevention of stroke. This is an area of 
active research and results of several ongoing trials are eagerly awaited. 
Hypertension  is  a  major  risk  factor  for  stroke  and  the  treatment  of 
hypertension  is  a  powerful  means  for  primary  prevention  of  stroke. 
Numerous randomized placebo controlled trials, using primarily diuretics and 
beta blockers, established this by the 1970's. 
Concern  about  cerebral  perfusion  in  patients  with  known cerebrovascular 
disease  and  especially  those  with  significant  carotid  disease,  meant 
extrapolation  of  primary  prevention  data  regarding  antihypertensive 
treatment was resisted till well into the 1990's. 
    There is the evidence that treatment of hypertension will reduce the risk of 
stroke in patients who have already suffered a stroke or TIA. This can be 
reviewed most efficiently  by looking at  a  recent systematic review of the 
topic  published in  the  Journal  STROKE in November 2003.  The authors, 
through an exhaustive search of  the  world  medical  literature,  identified  7 
placebo controlled trials that assessed the effect of lowering blood pressure in 
patients  with  prior  stoke  or  TIA.  They  used  meta-analytic  techniques  to 
combine these results and came to several not unexpected conclusions. The 
authors reported the results as odds ratios . The outcome, recurrent stroke, 
occurred in 11.46% of the placebo group, and 8.86% of the treatment group. 
(RR77%, RRR23%, ARR2.6%, NNT 38, p=0.005). Interestingly these results 
were  heterogeneous  depending  on  the  agent  used,  but  please  use  caution 
interpreting the results, as the numbers are small in each drug class except 
diuretics. 
Overall diuretics decreased the risk of recurrent stroke, ACE-I reduced the 
risk of MI and the combination of both drugs reduced both. Four of the seven 
trials used fixed drug combinations and enrolled both hypertensive and non 
hypertensive patients, bringing up a lively debate on whether the effects seen 
are  related  to  the  drugs  used,  or  the  blood  pressure  drops  seen,  in  the 
treatment arms. If the effects seen were due to the blood pressure drop, this 
brings in to play the question of the definitions of hypertension and target 
blood pressures. 
Atrial fibrillation is a potent risk factor for ischemic stroke. This dysrhythmia 
affects 2-5% of the general population over the age of 60, but is found in 
15% of all stroke patients. The use of anticoagulation with warfarin is now 
well established as the preferred method for primary prevention of stroke in 
this patient population, as long as the patient is not considered low risk. (Low 
risk  patients  have  no  history  of  previous  stroke  or  TIA,  no  treated  or 
untreated  hypertension,  no  diabetes,  and  no  symptomatic  coronary  artery 
disease.)17 In  low  risk  patients  there  is  no  substantive  advantage  for 
anticoagulation over antiplatelet agents. 
       Secondary prevention for a patient who has already suffered a stroke or a 
TIA  associated  with  atrial  fibrillation-  This  was  addressed  in  1995  by  a 
Cochrane Review. This review looked at the world literature in a systematic 
fashion, and performed a meta-analysis on the results. It combined the results 
of the EAFT from 1993 and VA-SPINAF from 1992. Between the 2 trials 
485 patients  were  included.  Anticoagulation  reduced the  risk  of  recurrent 
stroke by nearly 2/3 and the risk of all vascular events over 1/3. (RR 39.5%, 
RRR 60.5%, p<0.0001, ARR 13.7%, NNT 7 for recurrent stroke). 
           In progress   trial 6105 patients with stroke or TIA within 5 previous 
years were randomized to perindopril+indapamide or placebo. At the end of 4 
years they reported a reduction in recurrent stroke of 28% and total major 
vascular events by 26% inpatients with or without hypertension. Combination 
therapy with perindopril plus indapamide reduced recurrent stroke by 43% 
perindopril alone had no significant impact.
         WARSS15-  2206 patients with a non cardio embolic ischemic stroke 
were randomized to warfarn (INR 1.4-2.8)or asprin(325mg ) .At the end of 
2years there was no difference between groups with respect to the primary 
endpoint (warfarn 17.8% VS asprin 16%) or the rate of major hemorrhage.
            In a similar multicentric perspective observational study in setting of 
primary  cause  throughout  India  Sabash  Kaul13 summarized  the  findings. 
During 12 months perindopril based treatment it was found that incidence of 
recurrent stroke was similar to that of progress.
            SPARCL 12 investigators assigned 4731 patients who had a stroke or 
TIA within 1-6 months before study entry had LDL level 100-190 and had no 
known  coronary  artery  disease  to  double  blind  treatment  with  80  gm 
atorvostatin per day or placebo .During 4-9 years absolute reduction in risk of 
fatal / nonfatal stroke was2.2% & 3.5% reduction in cardiovascular events 
.There was a small increase in incidence of haemorrhage stroke. 
             Graeme30Quotes that elevation of plasma homocysteine is associated 
with laboratory evidence of atherogenesis and thombosis and epidemiological 
evidence  of  an  increased  risk  of  ischemic  stroke,  independent  of   other 
vascular risk factors. The vitamins in stroke prevention trial and the vitamins 
to  prevent  stroke  trial  show  insufficient  evidence  to  recommend  routine 
screening and treatment with folic acid B12 and B6.
                      Materials and methods
This study was conducted during January 2006 to December 2007 at 
Madras institute of neurology, Government General Hospital, Chennai.
 Patients  with  clinical  features  suggestive  of  second  or  subsequent 
strokes were taken up for study. All were subjected to CT/MRI scan of brain.
Inclusion criteria
1. All  the  patients  with  clinical  features  suggestive  of  second  or 
subsequent stroke.
2. Imaging showing ischemic infarcts in the brain
Exclusion criteria 
               1. First ever episode of stroke 
               2. Evolving stroke.
3. Imaging showing evidence of hemorrhage.
4. Imaging showing evidence of venous infarct.
Patients’ details regarding age, sex, and family history, risk factors like 
hypertension, diabetes mellitus, hypercholesterolemia, valvular heart disease, 
atrial fibrillation, trauma, smoking, and substance abuse were recorded. The 
onset and details of the symptoms and clinical signs were noted during each 
stroke  episode  from the  patient  or  close  relative  and the  old  records.  All 
patients had detailed neurological examination.
All  patients  underwent  a  basic  investigation  protocol  that  included 
complete   blood   counts  ,  erythrocyte  sedimentation rate,  blood  glucose, 
urea ,creatinine, electrolytes, lipid  profile (triglycerides, total cholesterol, and 
fractions)  CT  brain,  chest  x-ray,  electrocardiogram;  transthoracic 
echocardiogram.
MRI  brain  with  MRA  and  DWI,  B-mode  carotid  ultrasonography, 
carotid and vertebral Doppler study had been done wherever indicated. 
Other laboratory tests such as homocysteine, fibrinogen, prothrombin 
time  ,   partial  activated  thromboplastin  time,  antinuclear  antibodies, 
anticardiolipin antibody, lupus anticoagulant auto antibodies (anti-SM, anti-
SSA, and anti-RNA),  were done in selected patients where clinical features 
indicated their need
Specific  studies  for the  detection of natural  anticoagulant  deficiency, 
such  as  measurement  of protein  C,  protein  S,  and  antithrombin  III,  were 
carried out for patients with an undetermined diagnosis and when personal or 
family  history  indicated  a  prothrombotic    disorder.  Investigations  done 
during previous stoke episodes were also recorded.
Observation and Results
A total of 52 patients admitted in Government General Hospital between January 
2005 and December 2006 with clinical features and neuroimaging suggestive of second 
or subsequent stroke were included in the study. 
  Sex Distribution
          (n=52) 
(Males: 61.54%, Females: 38.46%)
males
femal
es
Age Distribution
Table-1
(n:52)
Age group Number of patients Percentage
20-30 1 1.9
30-40 1 1.9
40-50 6 11.5
50-60 8 15.38
60-70 24 46.15
70-80 12 23.07
Mortality in recurrent stroke
Table-2
(n:52)
Death No of patients Percentage
Within one month 2 4
Within one year 4 8
At the end of two years 7 14
 Incidence of stroke recurrence
Table-3
Period of occurrence No of patients
(n=52)
percentage
First month 1 2
First 6 months 6 12
 Within 1 One year 8 16
End of 2 years 13 26
3rd or subsequent 39 75
Vascular territory involved in Ischemic strokes
Table-4
Vascular  territory 
involved
First stroke Subsequent strokes
Number  of 
patients
percentage Number  of 
patients
Percentage
Middle  cerebral 
artery
35 67.31 30 85.71
Posterior  cerebral 
artery
5 9.61 1 20
Anterior  cerebral 
artery
4 7.7 0 0
Verebrobasilar 
artery
6 11.5 6 33.33
Multiple artery 2 3.84 0 0
(Only ischemic strokes were included in this study)
Risk factors identified during first & subsequent strokes
Table-5
Risk factors First stroke Subsequent 
stroke
atherosclerotic Number
Of 
patients 
percentage No of patients percentage
Hypertention 32                     61.54 8 
15.38
Diabetes 
mellitus
16                      30.77 2 
3.84 
Dyslipidemia 12                       23.08 2 
3.84
Smoking 30                       57.69 4 
7.7
Alcoholism 20                        38.46 4 
7.7
More  than  3  out  of  the  following  5  risk  factors  namely  hypertension  diabetes, 
dyslipidemia, smoking and alcoholism was present in 40 cases, (76.92%) as persistent 
causes, 2 out of 5 in 12 (23.08%).
Non atherosclerotic risk factors
Table-6
Risk factors Number  of 
patients
Percentage
Valvular heart disease 8 15.38
Ischemic heart disease 10 19.23
Patent  foramen  ovale+atrial  septal 
aneurysm
1 1.92
Aortoareritis 1 1.92
Among the valvular heart disease 6 out of 8 were rheumatic heart disease- mitral 
stenosis with atrial fibrillation, one was Aortic stenosis with atrial fibrillation  and one 
was infective endocarditis. All the 10 (19.23%) ischemic heart disease patients were in 
congestive heart failure during the recurrent stroke episode.
Patent foramen ovale with atrial septum aneurysm was detected during the first 
recurrent stroke. The aortic arteritis patient was on irregular therapy – steroids. The first 
recurrence occurred during drug withdrawal. 
Treatment and its effect on stoke free interval & recurrences
Table-7
 Treatment  &  number  of 
cases
Stroke free interval         Recurrences
(years) Number 
percentage
Hypertension (32) 1.5 15                       46.87
Asprin           (52) 2 10                       19.23
Dyslipidemia(12) 2 0                            0
All  the 32 cases of hypertension were on anti  hypertensive and the recurrent  stroke 
occurred during the non compliance. The mean stroke free interval was 1.5 years while 
on regular treatment recurrence occurred on drug withdrawal.
Ten  of  the  cases  had  stopped  asprin  for  more  than  a  month  accounting  for 
subsequent episode of stroke. The mean stroke free interval was 2 years with good drug 
compliance. 
All the 12 patients with dyslipidemia had elevated LDL and were on 20 mg/ day 
of atorvostatin. The stroke free interval was 2 years .Recurrence was not reported on 2 
cases which had stopped the drug for a period of one month. 
                    Discussion
Only ischemic type of stroke patients was included in this study. 61% of them 
were  males  showing  a  male  preponderance.  Age  group  60-70  had  the  maximum 
recurrence stroke (46.15%).This was similar to Jung B et al's 5 report. 
        The one month mortality rate was 4%, one month stroke recurrence rate 2%, and 1 
to 12 month stroke recurrence as 16% in this study. In Carolene jackson's e al’s 16 study 
they were 3.81%,2.11%, and 1.24%  respectively. This study shows similar one month 
mortality rate and more incidences of late recurrence.
Middle cerebral artery was the commonest vascular territory involved(67.31%) in this 
study as it was in all other recurrent stroke studies .Most of the recurrence was of the 
same arterial territory -the middle cerebral artery region (85.71%). 
Hypertension was found to be the risk factor in majority of cases (61.54%) and 
diabetes 30.77% in this study. In Jung B et al's  5 study hyperlipidemia was the major 
associated risk factor. In Perth community study1 diabetes mellitus was reported in 95% 
of cases while if is 30.77% in this study. 
In this study an attempt was made to analyze the cumulative effect of risk factors on the 
recurrence of stroke. It was clearly shown that addition of one  or more risk factors to 
the existing one increases the chance of developing recurrence. For example when a 
hypertensive develops diabetes and dyslipidemia he has more likelihood of developing 
the next stroke.  
This study showed an incidence of 15.38% of valvular heart diseases and 19.23% 
of ischemic heart disease – showing a marked increase in the incidence of valvular heart 
disease as a cause recurrent stroke. While Gold stein et al 4 report 30 day recurrence rate 
of 4.39% with cardio embolic source of other than valvular heart disease.     
       During the first recurrence we could identify a case of Patent foramen ovale with 
atrial  septal  aneurysm.  Masse  et  al’s32 recommendation  that  all  cryptogenic  stokes 
should be reevaluated proved fruitful.
This  study  shows  stroke  free  interval  of  1.5  years  (mean)  while  on 
Antihyperensive therapy, 2 years each for patients who were an aspirin and  atorvostatin. 
Progress  study  14 reports  a  reduction  in  recurrent  stroke of  28%  with  perindopril  and 
indapamide.  The event rate was estimated to be 18% with Asprin therapy by antiplatelet 
trialists’ collaboration  21.The reduction in risk of fatal and non fatal stroke was 2.2% 
with use of statin by Sparcl investigators 12. 
Comparison  between  near  similar  studies  had  been  made.  Other  observations 
made  were:  Hypertension  was  the  large  single  contributor  and  patients  on  Anti 
hypertensives  had a comparable stroke free interval. Asprin was effective in prolonging 
the stroke  interval. Statin had an added on effect in prolonging stroke free interval. 
Biomarkers  like  high  sensitivity  C-reactive  protein  (hs-CRP)  and  Liporotein 
associated phospholipase A2 (LP-PLA2) are found to predict recurrent stroke risk. Statins 
appear to lower hs-CRP levels33. A better understanding of these biomarkers may lead to 
use of prophylactic treatments to reduce risk of people suffering debilitating strokes.
            Early recurrent ischemic lesions detected by diffusion weighted image study can 
predict  (1)  the  presence  of  higher  grade  of  stenosis  in  intracranial  large  artery 
atherosclerosis subtype of stroke (2) possibility of good recanalization in cardioembolic 
– ischemic strokes 7
The recurrent stroke events are relatively small. Confounding factors such as age, 
sex and co morbid illnesses makes the analysis of prognosis difficult. These limitations 
highlight the need for pooled multivariate analysis of prognosis among different stroke 
subtypes  using  individual  patient  data  from  large  stroke  cohort  studies  to  increase 
number of patients and outcome events and allow for control of confounding factors. 
      As a stroke survivor or a caregiver for a stroke survivor, one should 
know that having a stroke puts the patient at greater risk for getting another 
stroke34.
Conclusion 
Recurrent strokes account for considerable amount of mortality and morbidity.
Pathological subtype breeds true to the index stroke.
Middle cerebral artery territory is the commonest site involved in recurrent stroke.
Hypertension was the risk factor found in majority of the recurrent episodes.
Presence  of  three  risk  factors  confers  the  maximum  risk  of  development  of 
subsequent strokes.
All patients deserve a repeat clinical examination and relevant investigations .This 
enables to identify  new risk factors in cryptogenic strokes and confirm existing and 
persisting / corrected risk factors. 
Aggressive  treatment  of  risk  factors  will  prolong  the  stroke  free  interval  and 
prevent the occurrence of recurrent stroke. 
Balance of benefits and risks associated with use of various secondary prevention 
treatments has to be decided on individual basis. 
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RECURRENT STROKE - PROFORMA
Name                                 Age:         Sex : DOA:              DOD:  MIN/IP no
:                    Address/Phone no: 
Occupation:
 Stroke Episodes First Second third fourth
Admission delay
(0-3h,3-6,6-12,12-24,24-48,>48h)
Interval between strokes
Symptoms
1.Headache
2.Nausea/Vomiting
3.Weakness of limbs
4.Numbness face/limbs
5.Mental changes
6.Neck pain
7.Dysphasia
8.Articulation disturbed
9.Impaired vision
10.Diplopia
11.Giddiness/vertigo
12.Dysphagia
13.Imbalance of gait/
in coordination
14.Convulsions-focal /
Generalized
15.Retention of urine
16.Fever
17.Others
18.Altered 
consciousness
CLINICAL EXAMINATION:
    Obesity              Pallor        Jaundice      Cyanosis        Lymph nodes
    Skin rash           Purpura      Xanthelasma
    Pulses :  carotid        vertebral          radial                dorsalis pedis  
    Blood pressure  :
    HMF :  conscious             drowsy                comatose 
                  MMSE :
                  Lobar functions :
    Speech :
     Visual acuity                                       visual field 
      pupils                                                  fundus
      EOM
      Facial palsy
     Other cranial nerves :   
      Bulk:
      Tone:
      Power  :   UL  :                                   LL  :
     Reflexes: Abdominal reflex :               cremastric :             
      BJ                                                       KJ
      TJ                                                       AJ
      SJ                                                       Clonus
      Plantar :       
Sensory :
Cerebellar :
EPS :
Bladder &bowel:  
CVS :
 RS   :
National Institute of Health Stroke scale(NIHSS)-score:
Modified Rankin Scale-score:
RISK FACTORS-PRESENT STROKE
1.BP on admission: RUL       LUL         at discharge       FH
2.Diabetes mellitus; Blood sugar          HbA1c
3.Cardiac diseases;a)IHD/MI              b)Atrial fibrillation
                                c)VHD:Rhematic/Prosthetic   
                                d)Congenital heart disease
4.Dyslipideamia:TC    LDL     HDL    TGL   VLDL      (mg/dl)
5.Tobacco:
6.Anemia:
7.Homocystinemia(>20/dl)
8.Alcohol:
9.TIA/Previos stroke:
10.Peripheral vascular disease:
11.Obesity:
12.Oral contraceptive use:
13.Drug abuse:
14.Family history of stroke:
15.Trauma:
16.Recent MI(<6weeks):
17.Deep venous thrombosis:
18.Polycythemia:
19.Others(specify….)                    Veg/Non-veg
INVESTIGATIONS:
Blood  : a)    Hb :           TC :                 DC :                      ESR:
              Sugar
              Urea         Creatinine 
              Total cholesterol                           Triglyceride 
                            LDL                     VLDL                     HDL
                      b)  BT                CT                  PT                 PTT
                           Platelet count                                            FDP
                           Peripheral smea
                      c)  CRP                 Homocysteine
                          ANA                          aCL                   LAC         
                          p-ANCA                                        c-ANCA
                          AT-III                          protein C / 
CXR –PA :
ECG         :
               ECHO      :  
            CT scan :    Distribution of hemispheric leision   0.normal
                                                                  1.cortical
                                                                  2.subcortical
                                                                  3.cortical&subcortical
                                                                  4.brainstem/cerebellum
                                                                  5.not applicable
                                  Location of leision:
        Frontal/parietal/temporal/occipital/basal   ganglia /thalamus/sub cortical white 
matter /cerebellum /midbrain /pons/medulla                            
              MRI :  Distribution of hemispheric leis ion  
                                                                  0. Normal
                                                                  1. Cortical
                                                                  2. Subcortical
                                                                  3. Cortical&subcortical
                                                                  4. brainstem/cerebellum
                                                                  5. Not applicable
           
                        Location of leis ion:
       Frontal/parietal/temporal/occipital/basal ganglia
                                                 /thalamus/sub cortical white matter/ 
                                                /cerebellum/midbrain/pons/medulla                 
                       DW
                       Perfusion
                       MRA 
           Doppler studies:    Carotid & Vertebral Angiography
DIAGNOSIS:
              Clinical                                        Radiological
PRESENTATIONS/RISK FACTORS/OUTCOME
Stroke first second thir
d
fourt
h
Date
Type of stroke
Vascular territory
Subtype of stroke
Hypertension
Diabetes
Smoking
Alcohol
Dyslipidemia
Valvular heart disease
Coronary artery 
disease
Others
Asprin
Other drugs
Drug compliance
Modified Rankin scale
A. Type of Stroke:
                 1.Ischemic 2.Hamorrhage 3.TIA
                 4. Others      5.Unknown
B.Vascular Territory:
                 1.Right MCA 2.Left MCA 3.Right ACA  
                 4. Left ACA 5.Right PCA 6.Left PCA 7.Vertebrobasilar
C.Subtype of ischemic stroke:                       
                 1a.Large artery extra cranial  atherosclerosis
                 1b.Large artery intracranial atherosclerosis
                  2. Cardio embolism
                  3. Small vessel occlusion
                  4. Stroke of other determined etiology
                  5. Stroke of other undetermined etiology
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